1 thought on “Industrial base of the biological industry”
Randal
In recent years, the Development and Reform Commission has adopted a series of measures to vigorously promote the agglomeration of the biological industry. At present, 22 national biological industry bases have been approved. It, to promote the agglomeration of the biological industry, guide the centralized investment of social resources to key areas, promote the healthy and rapid development of the biological industry in my country, promote the formation of unique biological industries in various places, and avoid repeated construction and decentralized resources. In accordance with the principles of "overall planning, exerting advantages, classification guidance, and steady advancement", during the "Eleventh Five -Year Plan" period, the National Development and Reform Commission selected areas with good industrial foundations, strong innovation capabilities, high marketization levels, and strong openness. Biological industry base and national high -tech industrial base. Up to now, Shijiazhuang, Shenzhen, Changsha, Beijing, Shanghai, Shanghai, Guangzhou, Wuhan, Kunming, Qingdao, Chengdu, Chongqing and other national biological industry bases, as well as Xi'an, Tianjin, Taizhou, Tonghua, Texas, Zhengzhou, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, and Nanning, Harbin, Hangzhou, Nanchang and other national high -tech industrial bases in the biological industry. Driven from national guidance and local promotion, it has greatly guided and promoted the agglomeration and development of the biological industry, and gradually cultivated three comprehensive biological industry bases in the Yangtze River Delta, Pearl River Delta, and Beijing -Tianjin -Hebei regions, as well as The spatial layout of several professional biological industry bases in the Northeast and the central and western regions, promote the concentration of biological enterprises, funds, technology, talents and other factors, accelerate the development of agglomeration and characteristics of the biological industry, and the agglomeration effect is initially manifested. In 2007, the total industrial output value of 12 national biological industry bases achieved a total of 314.5 billion yuan, an increase of 21%year -on -year, accounting for nearly half of the national biological industry. In order to promote the agglomeration and development of the biological industry, through the improvement of institutions and mobilizing resources, a series of supporting policies have been introduced, which has laid a good foundation for vigorously developing a number of biological industry bases. The construction of the base has played a significant role in creating a major role in creating an environment for the development of the biological industry, the large -scale gathering of domestic and foreign biological industry resources, optimizing the structure and layout of the biological industry, forming an international competitive biological industry growth, radiation and driving the rapid development of my country's biological industry. Essence The first batch of national biological industry bases (June 2005) Shijiazhuang base The special base relies on Shijiazhuang Economic and Technological Development Zone. There are more than 40 related biological companies such as Four Medicine Co., Ltd., with a total investment of over 10 billion yuan. At present, there are 178 key construction projects, divided into four categories: one is the field of chemical pharmaceuticals; the other is the field of biopharmaceuticals; the third is the field of modern Chinese medicine; the fourth is the field of public supporting facilities. In 2006, sales revenue was 28 billion yuan. In construction targets by 2012, the annual output value of the biological industry will reach 48.5 billion yuan. Changchun base The characteristic base will consist of three major modules: the core area of the pharmaceutical industry is located in the Changchun High -tech Industrial Development Zone, the core area of the biological industry is in the Changchun Economic and Technological Development Zone, and the core area of the biological agriculture is located in the city. Dong's Jingyue Lake Tourism Economic Development Zone. The area is 13.4 square kilometers. This is currently the largest vaccine and gene drug production base in Asia. In the field of biological manufacturing, Changchun Dacheng Industrial Group is the world's largest lysine producer. In the field of biological energy, ethanol gasoline projects are the only pilot cities in the country; Dacheng Group invested 10 billion yuan an annual output of 1 million tons of chemical alcohol projects as one of the country's largest chemical alcohol projects. Inning targets By 2010, the annual output value of the biological industry will reach 70 billion to 100 billion yuan. It Shenzhen base The core area of the characteristic is Shenzhen High -tech Industrial Park. The expansion area is two areas: Guangming and South Australia. Industrial land is nearly 3 square kilometers. In 2006, the number of companies with sales revenue exceeded 10 million yuan, with a number of companies with an output value of 100 million to 1 billion yuan. In the establishment of a complete biological industry technology support platform and industrial supporting system, Shenzhen has become the most market -oriented achievements in domestic marketization and the most complete achievements, the most competitive innovative drug research and development and industrialization base, and the technical content The highest medical device product production base. Inning targets By 2010, the annual output value of the biological industry will reach 70 billion to 100 billion yuan. The second batch of national biological industry bases (October 2006) Changsha base The characteristic is the first national biological industry base in the central region of my country. The base has formed 11 pharmaceutical industry groups. Among them, traditional Chinese medicine detoxification drugs are ranked first in the country, biological vaccine and antibiotic preparations in the central and southern region, and weight loss health products ranked third in the country, and the standardized extract of traditional Chinese medicine. In 2007, the base achieved total industrial output value of 7.063 billion yuan. In construction targets By 2015, the annual output value of the biological industry will reach 80 billion yuan. Guangzhou base The special base planning consists of two core areas, extended areas, and radiation areas. The overall planned area is about 13 square kilometers. Focus on the development of four major biomedical fields such as genetic engineering drugs, modern Chinese medicine, chemical synthesis and innovation drugs, and marine drugs, and focus on developing biological agriculture and promoting the development of biological services (biotechnology research and development, etc.). There are more than 300 biological enterprises, more than 70 of them, and 19 have an annual output value of over 100 million yuan. The scale and benefits of Guangzhou Pharmaceutical Group are at the forefront of the country's pharmaceutical industry. In 2007, the total output value of Guangzhou's biological industry completed was about 35.8 billion yuan, accounting for 12.5%of the city's high -tech product output value. Inning targets By 2010, the annual output value of the biological industry will reach 100 billion yuan of industrial scale. The Shanghai base The features according to the "1 4" architecture for space layout. "1" is a core area, which is Zhangjiang High Technology Park; "4" is four expansion areas. Focus on the development of new products in the fields of genetic engineering drugs, modern Chinese medicine, chemical synthetic innovation drugs, biomedical engineering and other fields, actively promote the implementation of major projects, promote the integration of large biological enterprise groups and the development of small and medium -sized enterprises, and gradually form an innovative system and distinctive industrial characteristics 2. R
In recent years, the Development and Reform Commission has adopted a series of measures to vigorously promote the agglomeration of the biological industry. At present, 22 national biological industry bases have been approved.
It, to promote the agglomeration of the biological industry, guide the centralized investment of social resources to key areas, promote the healthy and rapid development of the biological industry in my country, promote the formation of unique biological industries in various places, and avoid repeated construction and decentralized resources. In accordance with the principles of "overall planning, exerting advantages, classification guidance, and steady advancement", during the "Eleventh Five -Year Plan" period, the National Development and Reform Commission selected areas with good industrial foundations, strong innovation capabilities, high marketization levels, and strong openness. Biological industry base and national high -tech industrial base. Up to now, Shijiazhuang, Shenzhen, Changsha, Beijing, Shanghai, Shanghai, Guangzhou, Wuhan, Kunming, Qingdao, Chengdu, Chongqing and other national biological industry bases, as well as Xi'an, Tianjin, Taizhou, Tonghua, Texas, Zhengzhou, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, Nanning, and Nanning, Harbin, Hangzhou, Nanchang and other national high -tech industrial bases in the biological industry.
Driven from national guidance and local promotion, it has greatly guided and promoted the agglomeration and development of the biological industry, and gradually cultivated three comprehensive biological industry bases in the Yangtze River Delta, Pearl River Delta, and Beijing -Tianjin -Hebei regions, as well as The spatial layout of several professional biological industry bases in the Northeast and the central and western regions, promote the concentration of biological enterprises, funds, technology, talents and other factors, accelerate the development of agglomeration and characteristics of the biological industry, and the agglomeration effect is initially manifested. In 2007, the total industrial output value of 12 national biological industry bases achieved a total of 314.5 billion yuan, an increase of 21%year -on -year, accounting for nearly half of the national biological industry. In order to promote the agglomeration and development of the biological industry, through the improvement of institutions and mobilizing resources, a series of supporting policies have been introduced, which has laid a good foundation for vigorously developing a number of biological industry bases. The construction of the base has played a significant role in creating a major role in creating an environment for the development of the biological industry, the large -scale gathering of domestic and foreign biological industry resources, optimizing the structure and layout of the biological industry, forming an international competitive biological industry growth, radiation and driving the rapid development of my country's biological industry. Essence
The first batch of national biological industry bases (June 2005)
Shijiazhuang base
The special base relies on Shijiazhuang Economic and Technological Development Zone. There are more than 40 related biological companies such as Four Medicine Co., Ltd., with a total investment of over 10 billion yuan. At present, there are 178 key construction projects, divided into four categories: one is the field of chemical pharmaceuticals; the other is the field of biopharmaceuticals; the third is the field of modern Chinese medicine; the fourth is the field of public supporting facilities. In 2006, sales revenue was 28 billion yuan.
In construction targets by 2012, the annual output value of the biological industry will reach 48.5 billion yuan.
Changchun base
The characteristic base will consist of three major modules: the core area of the pharmaceutical industry is located in the Changchun High -tech Industrial Development Zone, the core area of the biological industry is in the Changchun Economic and Technological Development Zone, and the core area of the biological agriculture is located in the city. Dong's Jingyue Lake Tourism Economic Development Zone. The area is 13.4 square kilometers.
This is currently the largest vaccine and gene drug production base in Asia. In the field of biological manufacturing, Changchun Dacheng Industrial Group is the world's largest lysine producer. In the field of biological energy, ethanol gasoline projects are the only pilot cities in the country; Dacheng Group invested 10 billion yuan an annual output of 1 million tons of chemical alcohol projects as one of the country's largest chemical alcohol projects.
Inning targets By 2010, the annual output value of the biological industry will reach 70 billion to 100 billion yuan.
It Shenzhen base
The core area of the characteristic is Shenzhen High -tech Industrial Park. The expansion area is two areas: Guangming and South Australia. Industrial land is nearly 3 square kilometers. In 2006, the number of companies with sales revenue exceeded 10 million yuan, with a number of companies with an output value of 100 million to 1 billion yuan.
In the establishment of a complete biological industry technology support platform and industrial supporting system, Shenzhen has become the most market -oriented achievements in domestic marketization and the most complete achievements, the most competitive innovative drug research and development and industrialization base, and the technical content The highest medical device product production base.
Inning targets By 2010, the annual output value of the biological industry will reach 70 billion to 100 billion yuan.
The second batch of national biological industry bases (October 2006)
Changsha base
The characteristic is the first national biological industry base in the central region of my country. The base has formed 11 pharmaceutical industry groups. Among them, traditional Chinese medicine detoxification drugs are ranked first in the country, biological vaccine and antibiotic preparations in the central and southern region, and weight loss health products ranked third in the country, and the standardized extract of traditional Chinese medicine. In 2007, the base achieved total industrial output value of 7.063 billion yuan.
In construction targets By 2015, the annual output value of the biological industry will reach 80 billion yuan.
Guangzhou base
The special base planning consists of two core areas, extended areas, and radiation areas. The overall planned area is about 13 square kilometers. Focus on the development of four major biomedical fields such as genetic engineering drugs, modern Chinese medicine, chemical synthesis and innovation drugs, and marine drugs, and focus on developing biological agriculture and promoting the development of biological services (biotechnology research and development, etc.). There are more than 300 biological enterprises, more than 70 of them, and 19 have an annual output value of over 100 million yuan. The scale and benefits of Guangzhou Pharmaceutical Group are at the forefront of the country's pharmaceutical industry. In 2007, the total output value of Guangzhou's biological industry completed was about 35.8 billion yuan, accounting for 12.5%of the city's high -tech product output value.
Inning targets By 2010, the annual output value of the biological industry will reach 100 billion yuan of industrial scale.
The Shanghai base
The features according to the "1 4" architecture for space layout. "1" is a core area, which is Zhangjiang High Technology Park; "4" is four expansion areas. Focus on the development of new products in the fields of genetic engineering drugs, modern Chinese medicine, chemical synthetic innovation drugs, biomedical engineering and other fields, actively promote the implementation of major projects, promote the integration of large biological enterprise groups and the development of small and medium -sized enterprises, and gradually form an innovative system and distinctive industrial characteristics 2. R